Suppr超能文献

新型氮杂环与壬二酸部分结构杂化物的合成及其对骨肉瘤细胞的特异性活性。

Synthesis of Novel Structural Hybrids between Aza-Heterocycles and Azelaic Acid Moiety with a Specific Activity on Osteosarcoma Cells.

机构信息

Department of Industrial Chemistry 'Toso Montanari', Alma Mater Studiorum University of Bologna Viale Del Risorgimento, 4 402136 Bologna, Italy.

Department of Pharmacy and Biotechnology, University of Bologna, Via Irnerio 48,40126 Bologna, Italy.

出版信息

Molecules. 2020 Jan 18;25(2):404. doi: 10.3390/molecules25020404.

Abstract

Nine compounds bearing pyridinyl (or piperidinyl, benzimidazolyl, benzotriazolyl) groups bound to an azelayl moiety through an amide bond were synthesized. The structural analogy with some histone deacetylase inhibitors inspired their syntheses, seeking new selective histone deacetylase inhibitors (HDACi). The azelayl moiety recalls part of 9-hydroxystearic acid, a cellular lipid showing antiproliferative activity toward cancer cells with HDAC as a molecular target. Azelayl derivatives bound to a benzothiazolyl moiety further proved to be active as HDACi. The novel compounds were tested on a panel of both normal and tumor cell lines. Non-specific induction of cytotoxicity was observed in the normal cell line, while three of them induced a biological effect only on the osteosarcoma (U2OS) cell line. One of them induced a change in nuclear shape and size. Cell-cycle alterations are associated with post-transcriptional modification of both H2/H3 and H4 histones. In line with recent studies, revealing unexpected HDAC7 function in osteoclasts, molecular docking studies on the active molecules predicted their proneness to interact with HDAC7. By reducing side effects associated with the action of the first-generation inhibitors, the herein reported compounds, thus, sound promising as selective HDACi.

摘要

合成了 9 种通过酰胺键与氮丙啶部分结合的带有吡啶基(或哌啶基、苯并咪唑基、苯并三唑基)的化合物。这些化合物的结构类似于一些组蛋白去乙酰化酶抑制剂,因此它们被合成出来,旨在寻找新的选择性组蛋白去乙酰化酶抑制剂(HDACi)。氮丙啶部分让人联想到 9-羟基硬脂酸的一部分,9-羟基硬脂酸是一种细胞脂质,对作为分子靶点的具有 HDAC 的癌细胞具有抗增殖活性。进一步证明与苯并噻唑基部分结合的氮丙啶衍生物是有效的 HDACi。这些新化合物在一系列正常和肿瘤细胞系上进行了测试。在正常细胞系中观察到非特异性诱导细胞毒性,而其中三种化合物仅在骨肉瘤(U2OS)细胞系上诱导出生物学效应。其中一种化合物诱导核形状和大小发生变化。细胞周期的改变与 H2/H3 和 H4 组蛋白的转录后修饰有关。与最近的研究一致,揭示了出人意料的 HDAC7 在破骨细胞中的功能,对活性分子的分子对接研究预测了它们与 HDAC7 相互作用的倾向。通过减少与第一代抑制剂作用相关的副作用,因此,本文报道的化合物有望成为选择性 HDACi。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b694/7024557/e8c9ad5f7742/molecules-25-00404-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验